Suggestions
Karen Malone
Rare Disease & Biomarker Expert - Pharmaceutical Strategy - Market Assessment
Karen Malone is a professional with over 10 years of industry experience in translational medicine, biomarker expertise, and commercial strategy within the rare disease therapeutics sector.
Her background includes working on various drug modalities and targets, spanning from prototype development to final patient trials, with a focus on new product planning and corporate strategy.
She has held roles such as Business Development Specialist at ProQR Therapeutics, Managing Director at Leiden Analytics, Business Consultant at ProQR Therapeutics, and Senior Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson.
Karen's educational background comprises a Ph.D. in Pathobiology from the University of Southern California and a B.S. in Microbiology with a minor in Economics from Arizona State University College of Liberal Arts and Sciences.
She has a track record of supporting change management, evaluating drug development assets, and utilizing data-driven planning approaches for new products in the rare disease space.
In addition, Karen has contributed to organizations like Good Biomarker Sciences, Centre for Human Drug Research, Crossbeta Biosciences B.V., Cleveland Clinic, and PaineWebber.
